The US Food and Drug Administration (FDA) has approved canakinumab (Ilaris) for the treatment of gout flares in adults who cannot be treated with NSAIDs, colchicine, or repeated courses of corticosteroids. The drug is also indicated for people who could not tolerate or had an inadequate response
Read Article
Dr. Jack Cush reviews the news and journal reports from RheumNow.com this past week.
Glucocorticoid Affects Weight, but not Blood Pressure in RA A pooled analysis of 5 RCTs shows that the effects of 2 years of low-dose glucocorticoid (GC) treatment in RA can significantly
Links:
Links:
A EULAR/American College of Rheumatology task force has established evidence based, up-to-date guidance and expert opinion on the evaluation, management and monitoring of patients with Haemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS), with the primary intent to
Read Article
Links:
Links:
Links:
Links:
NIH researchers have have described a novel autoinflammatory disorder called "Lyn kinase-associated vasculopathy and liver fibrosis" (LAVLI), based on a mutation in the LYN gene (that encodes the Lyn kinase protein). They discovered that increased Lyn kinase activity promotes systemic
Read Article
Links:
Links:
Links:
Links:
Dr. Jack Cush reviews highlight abstracts and sessions - covering lupus, RA, gout, Still's disease, safety data, AI in medicine and more - from last week's EULAR 2023 Congress held in Milan, Italy.
Read Article
AOSD: Young vs. Elderly Onset AOSDis an autoinflammatory condition characterized by fevers, arthritis, and rash. It is considered an orphan disease because of its low prevalence - it is reported anywhere between 16 to 40 per ten million. https://t.co/bB2mpul3j7 https://t.co/ic6mY04ddF
Links:
Links:
